Navigation Links
AbbVie to Host Second-Quarter Earnings Conference Call
Date:7/23/2014

or, as the case may be, Shire's experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this announcement could cause AbbVie's plans with respect to Shire, AbbVie's or Shire's actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this announcement are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie is set forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K, which has been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Neither AbbVie nor Shire undertakes any obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


'/>"/>
SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
2. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
3. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
4. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
5. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
6. AbbVie Reports Third-Quarter 2013 Financial Results
7. AbbVie Named a Science Top Employer
8. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
9. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
10. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)...   Hospira, Inc. (NYSE: HSP ... infusion technologies, today announced that the company will present ... Wednesday, Jan. 14, 2015, in San Francisco.  ... 10:30 a.m. Pacific time on Wednesday, Jan. 14, 2015.  ... a live audiocast accessible via the Investor Relations section ...
(Date:12/19/2014)... 19, 2014 In today,s rapidly changing, ... communication tools are essential for survival. The world ... consumers, desires, preferences, and unmet needs are evolving ... groups across all industries are continually searching for ... the adoption of new market research techniques like ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... of Sustainable, Organic Livestock and ... ... Neptune Industries,Inc. (OTC Bulletin Board: NPDI), a next generation aquaculture technology,company ... production, and related,natural and organic food products, announced today that Phase ...
... Open Label Trial Published in Online Edition ... of ... reduced hemolysis and improved fatigue, overall,quality of life and anemia in ... nocturnal hemoglobinuria (PNH), according,to an analysis of the Phase III SHEPHERD ...
Cached Medicine Technology:Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 2Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 3Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM) 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 2Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 5Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 6Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 7
(Date:12/22/2014)... The MedTech industry is gearing up for new ... of PartnerTech AB of Sweden, is prepared to facilitate the ... Certification. , All signs point to growth in the MedTech ... a repeal of the excise tax originally levied to fund ... annual growth of 9.3% and PartnerTech Inc. is prepared to ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Christmas is days away, and last minute gifts ... solution that will please: the Sublime Gift Card . ... $25 up to $350," says Kathy Heshelow, founder of ... wide array of skin care products and Skin Brushes." , ... , Gift delivery past shipping deadlines, or those last ...
(Date:12/22/2014)... OAK BROOK, Ill. (PRWEB) December 21, 2014 ... receive radiologist recommendations for chest computed tomography (CT) ... have clinically relevant findings, including cancer, according to ... Radiology. , Researchers said the findings show ... chest X-rays represent valuable contributions to patient care. ...
(Date:12/22/2014)... Parker & Sons, Inc. a reliable and ... contracting services reports a record number of favorable reviews ... 2014. As a company that has served the greater ... Sons is a business that is focused on excellent ... other top quality companies in Arizona that are focused ...
Breaking Medicine News(10 mins):Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... kids is almost a nightmare to their respective parents, ... Researchers identified three factors that may increase a child's ... the disease that does not respond to commonly used ... before their first birthday which is also called symptomatic ...
... Female sexual dysfunction is associated with loss of libido, ... who have attained their menopause or whose ovaries had ... serve as an effective treatment in such sexual dysfunction, ... meeting of the American Urological Association in Anaheim, California. ...
... to improve sexual function among the hypertensive men with ... is the disease process itself, probably from reduced vascular ... a study evaluated hypertensive men with erectile dysfunction and ... 7.3% before losartan therapy to 58.5 % after losartan ...
... the current New England Journal of Medicine that an experimental ... men suffering from hemophilia. This method shows signs of ... clotting protein they lack. None of the patients suffers ... ,The study was designed only to test the safety and ...
... high doses of vitamin E may help fight diabetes. ... the world with many ravaging complications, affecting millions of ... damage, kidney failure, non healing ulcers all over the ... system. ,Diabetes is caused by the deficiency of ...
... latest mantra of Pfizer. The pharmaceutical giant has announced ... hardest hit by the AIDS virus. The decision by the ... Government winning a landmark case against pharmaceutical companies. In ... Diflucan will be given free of cost to battle HIV ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: